---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-25-000036"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:52:13.232856+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data

## Summary
- Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.
- Cash $100.6M as of Mar 31, down from $112.4M; company expects runway into 2027.
- CFO Gemma Brown terminated Apr 30 in restructuring; CEO William Enright named principal financial officer, Brown stays as principal accounting officer until successor.
- HBV003 trial: 33% (15/45) of low baseline HBsAg participants achieved ≥1 log decline; 71% met NUC discontinuation criteria; no SAEs.
- IM-PROVE II: 25% (2/8) of participants with baseline HBsAg <1000 IU/mL reached functional cure; all seroconverted.

## SEC filing metadata
- accession: 0001828185-25-000036
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/brns-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-25-000036
- JSON: https://secwatch.observer/filing/0001828185-25-000036.json
- Plain text: https://secwatch.observer/filing/0001828185-25-000036.txt

## Key facts
- Executive change
  Gemma Brown was appointed as principal accounting officer at Barinthus Biotherapeutics plc..
  - Action: appointed
  - Role: principal accounting officer
  source text: and Ms. Brown as principal accounting officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm
- Executive change
  William Enright was appointed as principal financial officer at Barinthus Biotherapeutics plc..
  - Action: appointed
  - Role: principal financial officer
  source text: appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm
- Executive change
  Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.